Jiuzhitang Power Regenerative Medicine Plus Cell Stem Cell Pharmaceutical Field

On September 14th, Jiuzhitang Yonghe Qihang fund initiated by Jiuzhitang signed an investment agreement with Stemedica Cell Technology Co., Ltd. in San Diego, USA. According to the agreement, Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. (hereinafter referred to as Jiuzhitang Maker) will introduce stem cell production technology and preparation platform of the world's top stem cell companies, and construction a commercial-grade stem cell production base that meets US and EU cGMP (Dynamic Drug Production Management Practices) standards in 3 to 5 years in Daxing Biomedical Industry Base in Beijing. 

According to relevant persons of Jiuzhitang, this marks the official entry of Jiuzhitang, a Chinese medicine company, into the field of stem cell drug research and development, clinical research and industrialization.

Strategic Transformation of Jiuzhitang

More and more clinical cases show that stem cell technology has an epoch-making significance for human medical development. Countries around the world have listed stem cells as strategic emerging industries that enhance international competitiveness in the field of human health. The data shows that by 2020, the global stem cell market will reach 400 billion US dollars, and the Chinese stem cell market will reach 120 billion yuan.

In May of this year, Jiuzhitang issued an announcement on the progress of the investment carried out by the M&A funds.

It is understood that the Yonghe Qihang Fund, established by Jiuzhitang, invested in Stemedica Cell Technology Co., Ltd. In USA. At the same time, Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. was established as the sole recipient of stem cell technology from the United States. Through the introduction of Stemedica's world-leading stem cell production technology and preparation platform, Jiuzhitang (Maker) has achieved the world's leading stem cell scale-up and solved the key technical problems of stem cell medicine. It is currently building a homologous stem cell production site in accordance with US and EU cGMP standards in Daxing District, Beijing, and will be used for human bone marrow mesenchymal stem cells and neural stem cell production. The platform has a total area of ​​4,500 square meters and is expected to be put into use in 2019.

Jiuzhitang said that the establishment of Jiuzhitang (Maker) marked an important transformation from the representative Chinese traditional Chinese medicine companies to an innovative one(请关注). In the future, a number of international multi-center clinical trials will be launched to promote the development of stem cell medicine technology.

It is understood that Jiuzhitang, as a century-old pharmaceutical company, strategically proposed in 2015: based on its own advantages in the Chinese medicine industry, leveraging the advantages of international stem cell technology, and re-electing the field of regenerative medicine, striving to integrate traditional Chinese medicine with stem cell frontier biotechnology. The combination has created a road to innovation for China's old-fashioned pharmaceutical companies.


Investment in the World's Leading Stem Cell Company

According to Jiuzhitang, Stemedica Inc. is located in San Diego, the United States' biotechnology and pharmaceutical industry gathering place. Its stem cell drug clinical trial for the treatment of Alzheimer's disease is the first one approved in the United States. It is one of the few FDA-certified companies who is permitted to conduct stem cell drug testing in the United States. It is one of the few companies in the world that can produce two kinds of stem cells including human bone marrow mesenchymal stem cells and human neural stem cells. Since its establishment in 2005, after 13 years of continuous investment in research and development, it has established a low-oxygen stem cell production platform with independent intellectual property rights and passed the US FDA cGMP certification. Under the premise of ensuring the quality of stem cells, the platform realizes the scale, standardization and traceability of stem cell production process, and achieves unprecedented stem cell amplification efficiency. In addition to its headquarters in San Diego and manufacturing facilities in San Diego, Stemedica has branches in Singapore and Lausanne, Switzerland.

Stemedica is conducting six clinical trials of stem cell therapy in the United States: ischemic stroke, chronic heart failure, Alzheimer's disease, skin photoaging, acute myocardial infarction, and traumatic brain injury. Ischemic brain Stroke and Chronic Heart Failure have completed clinical Phase II trials and published several high-level academic papers, and the clinical study of Alzheimer's disease is the first clinical study in the United States using stem cells to treat the disease. In addition, Stemedica has conducted 10 clinical studies in Switzerland, Kazakhstan, and Mexico. At the same time, a variety of health-grade products have been developed using stem cell factors secreted by clinical-grade stem cells, which are used in plastic surgery, anti-aging and beauty. Stemedica is currently conducting research on cancer vaccines using proprietary stem cell technology.

At present, there are no approved stem cell drugs in China. Jiuzhitang said that from the perspective of the industry, all governments have increased their support for stem cell and regenerative medicine policies. The market potential is huge in the future. The market scale will grow rapidly in the next five years, and the industry has broad prospects for development. Domestic enterprises mostly provide stem cell storage and supply services and medical beauty services rather than focusing on stem cell drugs. Stemedica's stem cell preparation technologies are technically feasible, and its technological leadership has the feasibility for stem cell medicine in the treatment of cardiovascular diseases, spinal cord injury, Alzheimer's disease and other diseases. Stemedica is worthy of investment.

In addition, Jiuzhitang introduced that Jiuzhitang (Maker) will cooperate with top hospitals in China to conduct multi-center clinical trials. Based on the results of good clinical trials of Stemedica in the United States, it will conduct stem cell clinical research on nervous system and cardiovascular and cerebrovascular diseases, and finally accelerate the stem cell drugs development and put the drug into use in China at an early date, expecting that people will benefit from the regenerative medicine in China. At the same time, Jiuzhitang Maker also signed a cooperation agreement with Mexico's Novastem Cell Technology and Kazakhstan's ALTACO Cell Technology to jointly establish an internationalized stem cell research and development platform.

According to relevant sources from Jiuzhitang, just earlier this month, the Ministry of Health of Kazakhstan signed a document approving a treatment plan for mesenchymal stem cells for acute myocardial infarction, marking the official commercialization of stem cell therapy in Kazakhstan. This is the first approved stem cell treatment program in the five countries of Central Asia, which has important demonstration significance for the future development of stem cell technology in Central Asia and the Middle East.